SARS-CoV-2 Mpro-IN-2

Modify Date: 2025-08-23 20:11:55

SARS-CoV-2 Mpro-IN-2 Structure
SARS-CoV-2 Mpro-IN-2 structure
Common Name SARS-CoV-2 Mpro-IN-2
CAS Number 2768834-39-3 Molecular Weight 475.39
Density N/A Boiling Point N/A
Molecular Formula C22H20Cl2N4O2S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of SARS-CoV-2 Mpro-IN-2


SARS-CoV-2 Mpro-IN-2 (compound GC-14) is a selective, low cytotoxic and non-covalent Mpro inhibitor (IC50=0.40 μM) with good anti-SARS-CoV-2 activity (EC50=1.1 μM). SARS-CoV-2 Mpro-IN-2 can be used in COVID-19 studies[1].

 Names

Name SARS-CoV-2 Mpro-IN-2

 SARS-CoV-2 Mpro-IN-2 Biological Activity

Description SARS-CoV-2 Mpro-IN-2 (compound GC-14) is a selective, low cytotoxic and non-covalent Mpro inhibitor (IC50=0.40 μM) with good anti-SARS-CoV-2 activity (EC50=1.1 μM). SARS-CoV-2 Mpro-IN-2 can be used in COVID-19 studies[1].
Related Catalog
Target

Mpro:0.40 μM (IC50)

In Vitro SARS-CoV-2 Mpro-IN-2 (0.01-100 μM; 4 h) shows low cytotoxicity in Vero E6 cells[1]. Cell Cytotoxicity Assay[1] Cell Line: Vero E6 cells Concentration: 0.01-100 μM Incubation Time: 4 h Result: Exhibited low cytotoxicity with a CC50 value of more than 100 μM.
In Vivo SARS-CoV-2 Mpro-IN-2 (2 mg/kg; i.v.; single) exhibits clearance rate (CL), mean residence time (MRT), and half-life (t1/2) are 3140 mL/h/kg, 0.40 h, and 0.36 h, respectively[1]. SARS-CoV-2 Mpro-IN-2 (10 mg/kg; p.o.; single) is rapidly absorbed, with a time-to-maximum concentration (Tmax) of 0.5 h, and shows a moderate pharmacokinetic profile including a favorable t1/2 (1.73 h), a maximum concentration (Cmax) 74.6 ng/mL, and an area under curve (AUC0-t) of 235 ng h/mL[1]. Animal Model: Male Sprague-Dawley rats[1]. Dosage: 2 mg/kg (for i.v.); 10 mg/kg (for p.o.). Administration: Intravenous injection or oral administration; single. Result: 1.19Pharmacokinetic Parameters of SARS-CoV-2 Mpro-IN-2 in Male Sprague-Dawley rats[1]. IV (2 mg/kg) PO (10 mg/kg) t1/2 (h) 0.36 1.73 Tmax (h) 0.08 0.5 Cmax (ng/mL) 1310 74.6 C0 (ng/mL) 1760 - AUC0-t (ng/mL•h) 627 235 AUC0-∞ (ng/mL•h) 637 230 MRT0-∞ (h) 0.40 2.45 CL (mL/h/kg) 3140 - F (%) - 7.2
References

[1]. Gao S, et al. Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity. J Med Chem. 2022 Sep 15:acs.jmedchem.2c01146.

 Chemical & Physical Properties

Molecular Formula C22H20Cl2N4O2S
Molecular Weight 475.39
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.